Welcome to our dedicated page for ARTIVA BIOTHERAPEUTICS SEC filings (Ticker: ARTV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artiva Biotherapeutics filings document its clinical-stage biotechnology business, Nasdaq-listed common stock and material-event reporting. Recent Form 8-K disclosures cover quarterly and annual financial results, Regulation FD updates on AlloNK® (AB-101) clinical data, and exhibits such as press releases and corporate presentations.
The filing record also describes governance and compensation matters, including board and officer appointments, employment arrangements, non-employee director compensation, inducement awards and an option-for-RSU exchange under the 2024 Equity Incentive Plan. Artiva’s disclosures identify AlloNK as an off-the-shelf NK cell therapy candidate used with anti-CD20 monoclonal antibodies in autoimmune-disease trials, alongside standard public-company capital-structure and securities information.
Artiva Biotherapeutics, Inc. President and CEO, who also serves as a director, reported an equity compensation change effective December 12, 2025. The company cancelled several employee stock options listed in the filing, with exercise prices ranging from $5.01 to $13.47 per share, covering multiple grants that were scheduled to vest over multi-year periods.
In exchange for the cancelled options, the reporting person received 869,136 restricted stock units under the company’s 2024 Equity Incentive Plan, recorded at a price of $0 per unit. Following this option-for-RSU exchange, the reporting person beneficially owned 1,213,135 shares of the company’s common stock, held directly.
Artiva Biotherapeutics, Inc. implemented a one-time exchange program allowing a limited group of employees, including its President and CEO Fred Aslan and COO/CLO Jennifer Bush, to surrender underwater stock options for restricted stock units (RSUs) under the 2024 Equity Incentive Plan. The goal is to enhance retention and better align employee incentives with stockholders by replacing options with little current value.
Dr. Aslan surrendered options to purchase 869,136 shares of common stock and Ms. Bush surrendered options to purchase 84,877 shares. In return, they received RSUs equal to their surrendered vested and unvested options. For the RSUs issued in exchange for vested options, 50% will vest on August 15, 2026, and 25% will vest on each of November 15, 2026, and February 15, 2027, with full acceleration if they are terminated other than for Cause or resign for Good Reason. RSUs issued for unvested options will vest between August 15, 2026, and February 15, 2029, with an additional six months of vesting acceleration upon those same termination events.
Artiva Biotherapeutics, Inc. (ARTV) reported an insider equity transaction by its Senior Vice President of Research and Development on a Form 4. On 11/15/2025, 1,375 shares of common stock were surrendered at a price of $3.25 per share, coded as an “F” transaction, which indicates shares withheld to cover taxes related to the vesting of restricted stock units. After this tax withholding event, the reporting person beneficially owned 39,591 shares of Artiva common stock directly. This was a routine administrative transaction tied to equity compensation rather than an open-market sale.
Artiva Biotherapeutics, Inc. (ARTV) reported an insider equity transaction by its Chief Tech Operations Officer. On 11/15/2025, 1,899 shares of common stock were withheld by the company at a price of $3.25 per share to cover income tax obligations tied to the vesting of restricted stock unit awards. After this tax withholding, the officer beneficially owns 78,183 shares of Artiva common stock in direct ownership. This filing is an administrative Form 4 disclosure of equity compensation and related tax settlement rather than an open-market buy or sell.
Artiva Biotherapeutics, Inc. (ARTV) reported an insider equity transaction by its COO, CLO, Secretary and Compliance Officer on a Form 4. On 11/15/2025, the officer had 3,055 shares of common stock withheld at a price of $3.25 per share. These shares were withheld by the company to cover income tax obligations associated with the vesting of restricted stock unit awards, rather than sold in an open-market transaction. After this tax withholding, the officer beneficially owned 148,048 shares of Artiva common stock directly.
Artiva Biotherapeutics, Inc. reported an insider equity transaction by its Chief Financial Officer, Neha Krishnamohan. On 11/15/2025, 3,490 shares of common stock were withheld by the company at a price of $3.25 per share to cover income tax obligations related to the vesting of restricted stock unit awards. After this tax withholding, the reporting person beneficially owns 99,356 shares of Artiva common stock directly.
Artiva Biotherapeutics (ARTV) President and CEO, who is also a director, reported routine equity transactions. On 11/15/2025, 6,347 shares of common stock were withheld by the company at $3.25 per share to cover income taxes from vesting restricted stock units. On 11/17/2025, the insider sold 6,375 shares of common stock at a weighted average price of $3.376 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on July 23, 2024. Following these transactions, the insider directly beneficially owned 343,999 shares of Artiva common stock.
Artiva Biotherapeutics (ARTV) disclosed initial safety and translational data for its investigational NK cell therapy AlloNK (AB-101) combined with rituximab or obinutuzumab in autoimmune diseases. As of October 1, 2025, 32 patients across refractory RA, Sjögren’s, systemic sclerosis, SLE and lupus nephritis were treated in outpatient settings, receiving 1B or 4B cells per dose. The regimen was generally well tolerated: no AlloNK-related Grade 3+ adverse events, no discontinuations, and no cytokine release syndrome, ICANS, GvHD or hypogammaglobulinemia; one hospitalization for an unrelated skin infection.
Translational findings showed all 23 analyzed patients had non-quantifiable peripheral CD19+ B cells by Day 13, corroborated by a high-sensitivity assay, with reconstitution patterns similar to CD19 auto-CAR-T. Artiva highlighted unmet need in refractory RA and plans to share initial clinical response data from >15 RA patients in H1 2026 and conduct FDA interactions in H1 2026 on a potential pivotal trial design.
Artiva Biotherapeutics (ARTV) disclosed initial safety and translational data for its investigational NK cell therapy AlloNK (AB-101) combined with rituximab or obinutuzumab in autoimmune diseases. As of October 1, 2025, 32 patients across refractory RA, Sjögren’s, systemic sclerosis, SLE and lupus nephritis were treated in outpatient settings, receiving 1B or 4B cells per dose. The regimen was generally well tolerated: no AlloNK-related Grade 3+ adverse events, no discontinuations, and no cytokine release syndrome, ICANS, GvHD or hypogammaglobulinemia; one hospitalization for an unrelated skin infection.
Translational findings showed all 23 analyzed patients had non-quantifiable peripheral CD19+ B cells by Day 13, corroborated by a high-sensitivity assay, with reconstitution patterns similar to CD19 auto-CAR-T. Artiva highlighted unmet need in refractory RA and plans to share initial clinical response data from >15 RA patients in H1 2026 and conduct FDA interactions in H1 2026 on a potential pivotal trial design.
Artiva Biotherapeutics (ARTV) reported Q3 2025 results marked by continued R&D investment and no product revenue. The company recorded a net loss of $21.5 million for the quarter and $63.1 million year‑to‑date. Q3 operating expenses were $22.9 million, driven by R&D of $17.6 million and G&A of $5.3 million. Net loss per share was $0.88 on 24.5 million weighted‑average shares.
Liquidity remained solid with $25.5 million in cash and cash equivalents and $97.5 million in short‑term investments, totaling $123.0 million as of September 30, 2025. The company used $62.0 million in cash for operating activities in the first nine months. Stockholders’ equity was $129.2 million, with total assets of $148.9 million. Management states existing cash, cash equivalents and investments will be sufficient to fund planned operations for at least one year from the issuance of these financial statements.
Artiva continues advancing NK cell programs, including AlloNK, under licensing and collaboration agreements with GC Cell. Shares outstanding were 24,544,904 as of October 31, 2025.
Artiva Biotherapeutics (ARTV) reported Q3 2025 results marked by continued R&D investment and no product revenue. The company recorded a net loss of $21.5 million for the quarter and $63.1 million year‑to‑date. Q3 operating expenses were $22.9 million, driven by R&D of $17.6 million and G&A of $5.3 million. Net loss per share was $0.88 on 24.5 million weighted‑average shares.
Liquidity remained solid with $25.5 million in cash and cash equivalents and $97.5 million in short‑term investments, totaling $123.0 million as of September 30, 2025. The company used $62.0 million in cash for operating activities in the first nine months. Stockholders’ equity was $129.2 million, with total assets of $148.9 million. Management states existing cash, cash equivalents and investments will be sufficient to fund planned operations for at least one year from the issuance of these financial statements.
Artiva continues advancing NK cell programs, including AlloNK, under licensing and collaboration agreements with GC Cell. Shares outstanding were 24,544,904 as of October 31, 2025.
Artiva Biotherapeutics filed a Form 8‑K stating it issued a press release announcing financial results for the quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1.
The company notes the information under Item 2.02, including Exhibit 99.1, is furnished and not filed, meaning it is not subject to Section 18 liability and is not incorporated into other filings unless expressly stated.
Artiva Biotherapeutics filed a Form 8‑K stating it issued a press release announcing financial results for the quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1.
The company notes the information under Item 2.02, including Exhibit 99.1, is furnished and not filed, meaning it is not subject to Section 18 liability and is not incorporated into other filings unless expressly stated.